| Formulation composition of botulinum toxins in clinical use. | |
| | |
MedLine Citation:
|
PMID: 20865839 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The use of botulinum toxin (BoNT) has now become the treatment of choice for a range of debilitating neuromuscular diseases and for aesthetic medicine. BoNT products are licensed as prescription-only medicines by the health authorities of each country in which they are approved. The authors describe here the current status with regard to BoNT formulations and detail more precisely what is in each product. These data have been presented previously, in a fragmented way, in papers that discuss characteristics of the BoNT products but not the formulations in detail. This information is essential for clinicians in order to enable informed decisions about which products they wish to use clinically. The authors have also examined developments that are either in progress or likely to occur, based on currently available information. |
| | |
Authors:
|
Andy Pickett; Karen Perrow |
Related Documents
:
|
14575169 - Hoof wall defects: chronic hoof wall separations and hoof wall cracks. 8249239 - Principles and techniques of anesthesia and analgesia for exotic practice. 19573269 - What are the real risks of sport-related concussion, and are they modifiable? 11419129 - Catchment management and the great barrier reef. 18755439 - Taking your radiology practice to the next level. 16759949 - Common procedures in other avian species. 10686649 - The first modern operating room in america. 20198999 - How to ensure patient observations lead to effective management of bradycardia. 20976269 - Consensus and discordance in the management of growth hormone-treated patients: results... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of drugs in dermatology : JDD Volume: 9 ISSN: 1545-9616 ISO Abbreviation: J Drugs Dermatol Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-27 Completed Date: 2010-10-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101160020 Medline TA: J Drugs Dermatol Country: United States |
Other Details:
|
Languages: eng Pagination: 1085-91 Citation Subset: IM |
Affiliation:
|
Biologicals Science and Technology, Ipsen Biopharm Limited, Wrexham, UK. andy.pickett@ipsen.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Botulinum Toxins
/
administration & dosage*,
chemistry* Chemistry, Pharmaceutical Drug Packaging Excipients Pharmaceutical Solutions |
| Chemical | |
Reg. No./Substance:
|
0/Botulinum Toxins; 0/Excipients; 0/Pharmaceutical Solutions |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Retrospective review of 500 patients treated with abobotulinumtoxinA.
Next Document: Failure of botulinum toxin treatment for localized vitiligo.